Evidence map›Paper›PMID 31858440›Full record

ReviewCurrent hematologic malignancy reports2019

What Does Chronic Myeloid Leukaemia Tell Us About Other Leukaemias?

Robert Peter Gale, Jane Apperley

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current hematologic malignancy reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Robert Peter GaleDepartment of Immunology and Inflammation, Centre for Haematology Research, Imperial College London, London, SW7 2AZ, UK. robertpetergale@alumni.ucla.edu.
Jane ApperleyDepartment of Immunology and Inflammation, Centre for Haematology Research, Imperial College London, London, SW7 2AZ, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewDetermine if therapy of chronic myeloid leukaemia (CML) is a model for treating other cancers. RECENT

findingsCML has a relatively homogeneous phenotype and genotype and is caused by one mutation, BCRABL1, in every instance. In contrast, most other leukaemias, haematologic cancers and solid cancer have more heterogeneous phenotypes and extraordinarily greater genotypic diversity and mutational complexity. Lesions learned from treating CML have little applicability to other leukaemias, haematologic cancers or solid cancer.

Indexed as

Disease ManagementDisease SusceptibilityFusion Proteins, bcr-ablHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMutationBCR-ABL1 fusion protein, humanFusion Proteins, bcr-ablAcute myeloid leukaemiaChronic myelogenous leukaemiaLeukaemia stem cellTherapy-free remissionTKI-therapyTyrosine kinase-inhibitor therapy

Identifiers

PMID31858440

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.